Page 42 - PACE: Advanced Prostate Cancer Consensus

STAMPEDE: Radiotherapy to the Primary Tumour for

Metastatic Prostate Cancer

OS by Metastatic Burden: Preplanned Subset Analysis

OS in low metastatic burden OS in high metastatic burden

100 100
Control
Radiotherapy 80 Control
Radiotherapy
80
Overall Survival (%) 60 Overall Survival (%) 60

40
40

20 20

HR, 0.68 (95% CI, 0.52–0.90; p = 0.007 HR, 1.07 (95% CI, 0.90–1.28; p = 0.420
0 0
0 6 12 18 24 30 36 42 48 54 0 6 12 18 24 30 36 42 48 54
Time since randomization (months) Time since randomization (months)
No. at risk (events) No. at risk (events)
Control 409 (5) 400 (9) 387 (17) 361 (17) 265 (12) 217 (22) 155 (16) 110 (8) 67 (5) 25 567 (11) 547 (42) 500 (58) 428 (41) 312 (27) 245 (43) 161 (20) 100 (7) 48 (3) 13
Radiotherapy 410 (1) 405 (4) 399 (12) 366 (12) 301 (19) 242 (10) 200 (15) 137 (11) 77 (5) 25 553 (10) 537 (38) 487 (48) 424 (59) 282 (30) 216 (31) 146 (19) 90 (14) 44 (5) 20

Parker CC, et al. Lancet 2018;392:2353-2366.